TL;DR
Ascletis has submitted two Investigational New Drug applications to the U.S. FDA for new obesity treatments. The filings cover a once-monthly peptide injection and a co-formulated version, advancing their clinical pipeline.
Ascletis has submitted two Investigational New Drug (IND) applications to the U.S. Food and Drug Administration (FDA) for its obesity drug candidates, ASC36 and ASC36_35. These filings mark a significant step toward initiating clinical trials in the United States, aiming to evaluate the safety and efficacy of these novel treatments for obesity.
The first application pertains to ASC36, a once-monthly peptide injection that acts as a amylin receptor agonist. The second involves ASC36_35, a co-formulation combining ASC36 with GLP-1R/GIPR agonist ASC35, also designed as a once-monthly injection. According to Ascletis, these filings are based on preclinical data demonstrating promising pharmacological activity and safety profiles.
Ascletis CEO, Dr. Jinzi Jiang, stated, “The submission of these INDs represents a critical milestone in our pipeline, as we aim to bring innovative obesity treatments to patients in need. We look forward to progressing these candidates into clinical trials.”
Potential Impact of Ascletis’ Obesity Drug Pipeline
This development is significant because it indicates that Ascletis is progressing its novel obesity treatments into human testing, which could expand options for obesity management. The drugs target mechanisms involving peptide hormones, which are increasingly recognized as effective pathways for weight loss. If successful, these therapies could add to the growing field of peptide-based obesity treatments, competing with existing drugs like GLP-1 receptor agonists.
Furthermore, advancing these candidates into clinical trials may enhance Ascletis’ position in the biotech sector and attract investor interest, especially given the global rise in obesity prevalence and demand for new therapies.
once monthly peptide weight loss injection
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Ascletis’ Obesity Treatment Development Timeline
Ascletis, a China-based biopharmaceutical company, has been developing peptide-based therapies for metabolic diseases. Prior to these IND submissions, the company conducted extensive preclinical studies demonstrating pharmacological activity and safety in animal models. The company has not yet disclosed specific timelines for clinical trial initiation but indicated that the IND filings are a prerequisite for human testing in the U.S., a key market for new drugs.
This move follows increasing global interest in peptide therapeutics for obesity, with several drugs already approved in other markets. Ascletis’ focus on once-monthly injections aims to improve patient adherence compared to daily treatments.
“The submission of these INDs represents a critical milestone in our pipeline, as we aim to bring innovative obesity treatments to patients in need. We look forward to progressing these candidates into clinical trials.”
— Dr. Jinzi Jiang, CEO of Ascletis
GLP-1 GIPR co-formulation injection
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Details About Clinical Trial Plans and Timing
It is not yet clear when Ascletis plans to initiate clinical trials following FDA approval of the INDs. Specific trial designs, patient populations, and timelines have not been disclosed, and regulatory review processes may influence the development schedule.obesity treatment peptide injections
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Next Steps for Ascletis’ Obesity Drug Candidates
Ascletis will await FDA review of its IND applications, which typically takes several months. Once approved, the company plans to initiate Phase 1 clinical trials to assess safety and dosage in humans. The outcomes of these trials will determine the further development pathway, including potential Phase 2 and 3 studies.
Additionally, the company may provide updates on trial timelines and results as development progresses, potentially within the next 12-18 months.
amylin receptor agonist injection
As an affiliate, we earn on qualifying purchases.
As an affiliate, we earn on qualifying purchases.
Key Questions
What are the main features of Ascletis’ obesity drug candidates?
Ascletis’ candidates include ASC36, a once-monthly peptide injection acting as an amylin receptor agonist, and ASC36_35, a co-formulation combining ASC36 with a GLP-1R/GIPR agonist. Both are designed for monthly administration to improve adherence and target metabolic pathways involved in weight regulation.
What is the significance of submitting IND applications?
Submitting INDs is a key regulatory step that allows a drug to enter clinical trials in the U.S. It indicates that the FDA has reviewed the preclinical data and found it sufficient to proceed with testing in humans.
When might clinical trials begin?
Ascletis has not announced specific dates. Typically, FDA review of INDs takes a few months, after which the company can start Phase 1 trials. The timeline depends on regulatory approval and trial planning.
Could these drugs compete with existing obesity treatments?
If successful, these drugs could offer new options for obesity management, especially with monthly dosing and novel mechanisms. They would enter a market with established therapies like GLP-1 receptor agonists, but their unique formulations could provide additional benefits.
What are the next steps after IND approval?
Following FDA approval of the INDs, Ascletis will likely initiate Phase 1 safety trials, followed by efficacy studies if results are favorable. The company will also monitor regulatory processes and may update the market on trial progress and timelines.
Source: primary
